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Abstract
Background: Irritable	bowel	syndrome	(IBS)	and	inflammatory	bowel	disease	(IBD)	
patients	report	similar	gastrointestinal	(GI)	symptoms,	yet	comparisons	of	symptom	
severity	between	groups	and	with	the	general	population	(GP)	are	lacking.
Methods: We	compared	Patient-	Reported	Outcomes	Measurement	 Information	
System	(PROMIS®)	GI	symptom	scales	measuring	gastro-	esophageal	reflux	(GER),	
disrupted	swallowing,	diarrhea,	bowel	 incontinence,	nausea/vomiting,	constipa-
tion,	belly	pain,	and	gas/bloating	in:	 (i)	USA	GP	sample,	 (ii)	 IBS	patients,	and	(iii)	
IBD	 patients	 from	 tertiary	 care	 and	 community	 populations.	 Symptom	 severity	
scores	were	based	on	T-	score	metric	with	mean	50±10	(standard	deviation)	rela-
tive	to	the	GP.
Key Results: Of	1643	patients	enrolled,	there	were	253	IBS	patients	(68%	F,	mean	
age	45±15	years),	213	IBD	patients	(46%	F,	mean	age	41±14	years),	and	1177	GP	
subjects	(57%	F,	mean	age	46±16	years).	IBS	patients	reported	greater	severity	of	
GER,	disrupted	swallowing,	nausea/vomiting,	belly	pain,	gas/bloating,	and	consti-
pation	symptoms	than	their	IBD	counterparts	(all	P<.05).	Compared	to	the	GP,	IBD	
patients	had	worse	belly	pain,	gas/bloating,	diarrhea,	and	bowel	incontinence,	but	
less	severe	GER	and	disrupted	swallowing	 (all	P<.05),	and	 IBS	patients	had	more	
severe	 nausea/vomiting,	 belly	 pain,	 gas/bloating,	 and	 constipation	 (all	 P<.05).	
Women	had	more	severe	belly	pain	and	gas/bloating	than	men,	whereas	men	had	
more	severe	bowel	incontinence	(all	P<.05).
Conclusion & Inferences: IBS	and	IBD	are	associated	with	more	severe	GI	symp-
toms	compared	to	the	GP	excluding	esophageal	symptoms.	Unlike	IBD,	IBS	is	not	
characterized	by	observable	GI	inflammation	but	patients	report	more	severe	upper	
and	lower	GI	symptoms.
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1  | INTRODUCTION
Irritable	bowel	syndrome	(IBS)	and	inflammatory	bowel	disease	(IBD)	
are	gastrointestinal	(GI)	disorders	that	are	associated	with	abdominal	
pain,	alteration	in	bowel	habits,	relapsing-	and-	remitting	courses,	and	
psychological	distress.1	In	comparison	to	IBS	in	which	disease	sever-
ity	is	usually	based	on	patient-	reported	symptoms,	current	research	in	
IBD	has	focused	on	the	use	of	serum,	fecal,	and	colonic	mucosal	in-
flammatory	biomarkers	as	surrogates	for	disease	severity.2–4	Relatively	
less	 studied	 are	 patient-	reported	 severity	 of	GI	 symptoms	between	
these	groups	and	the	general	population	(GP).
IBS	is	a	functional	bowel	disorder	in	which	abdominal	pain	is	as-
sociated	with	changes	 in	bowel	habits	and	disordered	defecation.	 It	
occurs	in	10%–20%	of	the	general	population	and	is	more	predomi-
nant	in	women	and	those	with	underlying	psychological	comorbidities	
or	 co-	existing	 functional	 disorders.5–7	 The	 etiology	 of	 IBS	 is	 multi-
factorial,	but	the	pathogenesis	 is	thought	to	be	due	to	dysregulated	
brain–gut	 interactions	 in	which	 peripheral	 and	 central	 sensitization	
can	occur.	Central	 sensitization	at	 the	 spinal	 cord	 and	brain	 level	 is	
associated	with	increased	activation	in	brain	regions	involved	in	emo-
tional	arousal	and	pain	modulation.8
Crohn’s	 disease	 (CD)	 and	 ulcerative	 colitis	 (UC)	 are	 chronic	
immune-	mediated	disorders	classified	as	IBDs	that	affect	less	than	1%	
of	 the	USA	population.9	 Increased	 prevalence	 is	 seen	 in	 genetically	
predisposed	 individuals	 and	 certain	 ethnic	 groups.	 These	 diseases	
are	thought	be	caused	by	chronic	dysregulation	of	mucosal	 immune	
function,	and	therapies	directed	against	suppression	or	modulation	of	
inflammation	are	generally	effective.
Although	the	extent	to	which	these	disease	processes	have	over-
lapping	 pathologies	 is	 controversial,10	 traditional	 thinking	 attributes	
the	etiology	of	pain	in	IBD	to	objective	inflammatory	changes	within	
the	bowel	and	associated	complications.	It	is	commonly	assumed	that	
worsened	symptom	severity	correlates	with	 increased	prevalence	of	
inflammatory	lesions	and	complications,	however,	this	simplistic	view	
of	pain	pathogenesis	does	not	account	for	the	fact	that	patients	with	
IBS	often	will	have	 similar	 complaints	without	objective	disease	pa-
thology.	While	 IBS	 and	 IBD	 have	 both	 been	 associated	with	worse	
general	health-	related	quality	of	life	(HRQOL),11	it	remains	unclear	the	
extent	that	specific	GI	symptoms	affect	patients.	GI	symptom	ques-
tionnaires	such	as	the	Gastrointestinal	Symptom	Rating	Scale	(GSRS)	
and	Quality	of	Life	in	Reflux	and	Dyspepsia	(QOLRD),	which	measure	
the	degree	of	GI	symptom	discomfort,	have	been	developed	but	have	
only	been	evaluated	in	patients	with	reflux	disease	and	IBS	and	may	
not	be	applicable	to	a	wider	range	of	GI	disorders	and	the	GP.12–15
The	NIH	Patient-	Reported	Outcomes	Measurement	 Information	
System	(PROMIS®)	GI	Symptom	Scales	assess	gastro-	esophageal	re-
flux	(GER),	disrupted	swallowing,	diarrhea,	bowel	incontinence,	nausea	
and	vomiting,	constipation,	GI	pain,	and	gas	and	bloating16	(Figure	1).	
The	PROMIS®	GI	instrument	measures	different	facets	of	each	symp-
tom	domain,	 including	frequency,	amount,	bothersomeness,	and	 im-
pact.	We	previously	found	that	the	prevalence	of	heartburn	was	not	
different	between	a	sample	of	the	USA	general	population	(GP)	and	a	
patient	group	comprised	of	 IBD	and	functional	GI	disorders,	but	re-
gurgitation	was	more	common	in	patients.17	In	this	study,	we	compare	
differences	in	upper	and	lower	GI	symptom	severity	between	patients	
with	 IBS,	 IBD,	 and	 the	GP,	 adjusting	 for	demographics.	We	also	as-
sess	 the	 effect	 of	 gender	 on	GI	 symptom	 severity.	We	hypothesize	
that	 the	 IBS	and	 IBD	patient	groups	will	 have	greater	 symptom	se-
verity	for	belly	pain	and	lower	GI	symptoms	(e.g.,	diarrhea,	constipa-
tion,	bowel	incontinence)	than	the	GP,	but	that	IBS	patients	will	have	
greater	severity	of	certain	GI	symptoms,	including	belly	pain,	gas	and	
bloating,	constipation	than	IBD	patients,	and	the	GP.	In	addition,	we	
F IGURE  1 Gastrointestinal	subdomains	measured	by	the	
PROMIS®	GI	Symptom	Scale.	The	eight	symptom	domains	and	the	
number	of	items	in	the	GI	PROMIS®	questionnaire	are	shown
G
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Belly pain 8 items
Gas and bloating 12 items
Diarrhea 5 items
Constipation 9 items
Bowel 
Incontinence 4 items
Gastroesophageal 
Reflux 13 items
Disrupted 
swallowing 7 items
Nausea and 
vomiting 4 items
Key Points
•	 Patients	with	irritable	bowel	syndrome	(IBS)	and	inflam-
matory	bowel	disease	(IBD)	have	similar	gastrointestinal	
(GI)	symptoms	but	studies	comparing	symptom	severity	
between	 these	 groups	 and	 the	 general	 population	 are	
lacking.
•	 IBS	patients	experience	worse	upper	and	lower	GI	symp-
toms	than	IBD	patients.	Patients	with	either	IBS	or	IBD	
experience	worse	epigastric	and	lower	GI	symptoms	than	
the	general	population,	but	comparable	or	less	severe	es-
ophageal	symptoms.
•	 Understanding	 the	 differences	 in	 symptom	 severity	 be-
tween	 patients	 will	 allow	 for	 improved	 symptom	
management.
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hypothesize	 that	women,	 in	 general,	 will	 report	 greater	 severity	 of	
belly	pain	and	gas	and	bloating,	as	demonstrated	in	previous	studies.18
2  | METHODS
2.1 | Selection of participants
This	 study	 recruited	 adult	 patients	 from	 a	 variety	 of	 academic	 and	
community-	based	gastroenterology	clinics.	 Inclusion	criteria	 for	 this	
cohort	were	as	follows:	(i)	age	18	or	older,	(ii)	able	to	speak,	read,	and	
understand	English,	(iii)	have	a	physician-	diagnosed	GI	disorder	includ-
ing	IBS	or	IBD	(CD	or	UC),	and	(iv)	able	to	provide	informed	consent.	
Patients	who	did	not	meet	all	of	 these	criteria	were	excluded	 from	
the	study.	Subjects	included	patients	previously	diagnosed	with	IBD	
seeking	care	at	Cedars-	Sinai	Medical	Center,	a	tertiary	center	in	Los	
Angeles,	and	a	specialty	clinic	at	the	University	of	Michigan,	patients	
previously	 diagnosed	 with	 IBS	 seeking	 care	 at	 a	 functional	 bowel	
disorders	 clinic	or	 responding	 to	 an	 advertisement	 for	 IBS	 research	
studies	at	the	University	of	California	Los	Angeles,	and	patients	with	
diverse	GI	conditions	seeking	care	at	a	general	GI	clinic	at	the	West	
Los	Angeles	Veterans	Affairs	Medical	Center.	Patients	with	IBS	who	
were	 recruited	 from	the	clinics	were	previously	diagnosed	with	 IBS	
using	the	Rome	III	criteria5	by	a	physician	with	expertise	in	IBS	before	
enrolling	 in	 this	 study.	Patients	with	 IBS	who	 responded	 to	 a	 com-
munity	advertisement	completed	a	Rome	III	questionnaire	and	under-
went	 a	medical	 history	 and	 physical	 examination	 by	 a	GI	 physician	
to	 confirm	 the	diagnosis	of	 IBS.	 In	 addition,	we	partnered	with	 the	
International	 Foundation	 for	 Functional	 Gastrointestinal	 Disorders	
(IFFGD)	to	survey	a	cohort	of	patients	with	diverse	functional	GI	dis-
orders	(FGIDs)	enrolled	in	IFFGD	mailing	lists.
All	patients	were	invited	to	complete	the	confidential	online	sur-
vey	 instrument,	administered	using	Survey	Monkey	software	 (http://
www.surveymonkey.com)	 and	 offered	 $25	 compensation.	 Patients	
without	Internet	access	could	request	a	paper	survey	be	sent	to	their	
home,	or	completed	in	clinic,	as	needed.	Patients	were	excluded	from	
participation	if	they	failed	to	provide	informed	consent,	had	a	history	
of	cognitive	impairment	that	would	interfere	with	participation,	or	 if	
they	 had	 any	 concurrent	medical	 or	 psychiatric	 condition	 that	 pre-
cluded	participation.
An	additional	group	of	randomly	selected	participants	designed	to	
represent	 the	GP	 in	 terms	of	 gender,	 ethnicity,	 race,	 and	 education	
level	based	on	the	2010	census	data	was	recruited	by	a	commercial	
survey	research	firm	(CINT,	http://www.cint.com)	which	administered	
the	survey.	Subjects	were	required	to	be	18	years	of	age	or	older	and	
able	to	read	English;	there	were	no	other	exclusion	criteria	applied	to	
the	GP	sample.
2.2 | Instruments
2.2.1 | PROMIS® GI Symptom Scales
The	 eight	 NIH	 PROMIS®	 GI	 symptom	 scales	 were	 developed	 to	
measure	 the	 breadth	 and	 depth	 of	 GI	 symptoms	 experienced	 by	
individuals	with	a	wide	range	of	digestive	disorders.	Unlike	disease-	
targeted	 measures	 for	 specific	 patient	 populations,	 the	 PROMIS® 
GI	 symptom	 scales	 were	 designed	 for	 symptom	 assessment	 in	 all	
individuals,	 whether	 within	 the	 GP	 or	 patient	 groups,	 who	 are	 ex-
periencing	 a	 GI	 symptom.	 The	 GI	 symptom	 scales	were	 developed	
following	 the	 criteria	 for	 qualitative	 and	 quantitative	 development	
of	 NIH	 PROMIS®	 measures	 with	 oversight	 of	 the	 NIH	 PROMIS® 
Steering	Committee.19–22	Details	of	the	construction	and	evaluation	
of	this	instrument	have	been	published.14	Factor	analyses	supported	
the	creation	of	the	eight	symptom	scales.	Symptom	severity	was	cal-
culated	from	a	scaled	score	in	each	category,	estimated	using	a	two-	
parameter	graded	response	model	with	the	mean	set	at	50	and	the	
standard	deviation	to	10	relative	to	the	USA	GP	with	higher	scores	
indicating	more	severe	symptomatology.
2.3 | Statistical analysis
We	calculated	descriptive	statistics	 for	patients	with	 IBS,	 IBD,	and	
the	GP.	We	performed	bivariate	analysis	between	groups	to	compare	
overall	age,	gender,	ethnicity,	education,	marital	status,	and	employ-
ment	status	using	a	χ2	test	for	categorical	variables	and	a	t	test	for	
continuous	 variables.	 To	 compare	GI	 symptom	 domain	 differences	
between	groups,	we	used	analysis	of	covariance	(ANCOVA)	control-
ling	for	age,	gender,	race/ethnicity,	education,	and	marital	status,	as	
these	differed	between	groups	and	could	affect	symptom	reporting.	
Main	effects	for	gender	were	assessed	within	the	pooled	sample	of	
GP,	IBS,	and	IBD	subjects.	Significance	was	defined	by	a	two-	tailed	
P<.05.
3  | RESULTS
3.1 | Clinical characteristics
Overall,	1643	patients	enrolled	in	this	study.	The	IBS	group	consisted	
of	253	patients	who	met	Rome	III	diagnostic	criteria,	confirmed	by	a	
physician,	and	had	no	evidence	of	organic	disease.	Among	these	pa-
tients,	28%	were	classified	as	having	IBS–constipation,	32%	IBS–di-
arrhea,	 29%	mixed,	 and	 11%	unknown	based	 on	Rome	 III	 criteria.5 
The	IBD	group	consisted	of	213	patients,	10%	were	of	IBD–unclas-
sified	subtype,	whereas	33%	had	Crohn’s	disease	and	57%	had	UC,	
which	 had	 previously	 been	 confirmed	 by	 accepted	 clinical,	 radio-
graphic,	 endoscopic,	 and/or	 histologic	 criteria.	 Table	1	 displays	 the	
number	of	patients	recruited	from	each	recruitment	site.	Table	2	lists	
the	demographic	information	from	the	IBS,	IBD,	and	general	popula-
tion	subgroup	(n=1177).	Significant	differences	between	the	IBS	and	
IBD	groups	and	the	GP	were	found	on	age	 (P=.008),	 female	gender	
(P=.005),	 race/ethnicity	 (P<.0001),	 education	 level	 (P<.001),	 marital	
status	(P=.016),	and	employment	status	(P=.042).
3.2 | GI symptom differences between groups
Table	3	shows	the	comparisons	of	symptom	severity	for	each	GI	do-
main	in	patients	with	IBS	or	IBD	to	the	GP.
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IBS vs GP.	 IBS	patients	reported	significantly	worse	symptoms	of	
belly	pain	(P<.0001),	nausea	and	vomiting	(P<.0001),	gas	and	bloating	
(P<.0001),	 diarrhea	 (P<.0001),	 and	 constipation	 (P<.0001)	 than	 the	
GP.	There	were	no	significant	differences	between	patients	with	IBS	
and	 the	GP	on	GER,	 disrupted	 swallowing,	 and	bowel	 incontinence	
(Figure	2).
Irritable 
bowel 
syndrome 
(IBS, n=253)
Inflammatory 
bowel disease 
(IBD, n=213)
General 
population (GP, 
n=1177) P value
Mean	age±SD	(years) 45±15 41±14 46±16 .008
Female	gender	(%) 68 46 57 .005
Ethnicity/race	(%)
Caucasian 56 58 73 <.0001
Hispanic 13 14 10
African-	American 18 11 12
Asian 10 11 3
Other 2.1 6.8 1.6
Education	(%)
Less	than	high	school 1.3 3.2 4.2 <.0001
High	school	graduate 33 36 60
College	graduate 37 40 26
Advanced	degree 29 21 9.9
Marital	status	(%)
Married 39 42 45 .016
Previously	married 23 15 22
Never	married 38 43 33
Employment	(%)
Employed/student 71 72 65 .042
Not	working 9.1 9.0 12
Retired 10 9.5 16
Disabled 9.5 10 7.5
IBS	subtype	(%)
IBS–constipation 28
IBS–diarrhea 32
IBS–mixed 29
Unknown 11
IBD	subtype	(%)
Crohn’s	disease 33
Ulcerative	colitis 57
Unclassified 10
TABLE  2 Patient	clinical	characteristics
Cedars Sinai 
Medical 
Center UCLA
VA Medical 
Center West 
Los Angeles
University of 
Michigan
IFFGD 
mailing 
list CINT
IBS 4 182 54 9 4 –
IBD 168 14 30 1 0 –
General	
Population
– – – – – 1177
IFFGD,	 International	 Foundation	 for	 Functional	 Gastrointestinal	 Disorders;	 UCLA,	 University	 of	
California	 Los	 Angeles;	 VA,	 veterans	 affairs;	 IBD,	 inflammatory	 bowel	 disease;	 IBS,	 irritable	 bowel	
syndrome.
TABLE  1 Recruitment	of	patients	based	
on	site
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IBD vs GP.	 Patients	 with	 IBD	 had	 significantly	 worse	 belly	 pain	
(P<.0001),	gas	and	bloating	(P=.0005),	diarrhea	(P<.0001),	and	bowel	
incontinence	(P=.004)	than	the	GP.	In	contrast,	patients	with	IBD	ex-
perienced	less	severe	symptoms	of	GER	(P<.0001)	and	disrupted	swal-
lowing	(P<.0001)	than	the	GP.	There	were	no	significant	differences	in	
the	severity	of	constipation	and	nausea	and	vomiting	between	these	
two	groups	(Figure	3).
IBS vs IBD.	As	shown	in	Figure	4,	after	controlling	for	age,	gender,	
race/ethnicity,	education,	and	marital	status,	most	GI	symptoms	were	
reported	 as	more	 severe	 by	 IBS	patients	 than	 IBD	patients:	 nausea	
and	vomiting	(F=22,	P<.0001),	GER	(F=32,	P<.0001),	disrupted	swal-
lowing	(F=20,	P<.0001),	belly	pain	(F=55,	P<.0001),	gas	and	bloating	
(F=42,	 P<.0001),	 and	 constipation	 (F=41,	 P<.0001).	 There	 were	 no	
significant	differences	in	the	severity	of	diarrhea	(F=0.06,	P=.80)	and	
bowel	 incontinence	 (F=0.19,	P=.69)	 between	 patients	with	 IBS	 and	
IBD	(Figure	4).
Main effects of gender.	 Three	 symptom	 domains	 differed	 signifi-
cantly	between	men	and	women	in	the	model.	Women	reported	more	
severe	belly	pain	 (P=.0026)	and	gas	and	bloating	 (P<.0001),	but	had	
less	severe	bowel	 incontinence	than	men	 (P<.0001).	Although	there	
was	a	 trend	 for	 less	 severe	disrupted	 swallowing	 in	women	vs	men	
(P=.054),	there	were	no	significant	differences	in	nausea	and	vomiting,	
diarrhea,	and	constipation.	There	were	no	significant	interactions	be-
tween	gender	and	group	for	any	of	the	symptom	domains.
4  | DISCUSSION
The	PROMIS®	 instruments	 are	 patient-	reported	outcome	measures	
that	have	been	applied	 to	 a	 variety	of	diseases.23–26	Our	 study	has	
been	uniquely	designed	to	allow	comparisons	of	symptom	severity	in	
patients	with	IBS,	IBD,	and	the	GP,	which	have	not	previously	been	
examined.	Our	main	findings	indicate	that	patients	with	IBS	have	more	
severe	upper	and	lower	GI	symptoms,	excluding	diarrhea	and	bowel	
incontinence,	than	patients	with	IBD.	In	addition,	we	found	that	pa-
tients	with	 IBS	and	 IBD	report	more	severe	epigastric	and	 lower	GI	
symptoms	 than	 the	GP,	but	 reported	esophageal	 symptom	severity	
that	is	comparable	or	less	severe	than	the	GP,	respectively.	Lastly,	the	
Symptom domain Subgroup Parameter P value T statistic
Gastro-	esophageal	reflux IBS 0.25 .73 0.35
IBD −4.9 <.0001 −6.5
Disrupted	swallowing IBS 0.03 .97 0.04
IBD −4.1 <.0001 −5.4
Nausea	and	vomiting IBS 3.2 <.0001 4.5
IBD −1.1 .14 −1.5
Belly	pain IBS 11.0 <.0001 15
IBD 4.2 <.0001 5.3
Gas	and	bloating IBS 8.8 <.0001 12
IBD 2.7 .0005 3.5
Diarrhea IBS 6.7 <.0001 8.5
IBD 6.9 <.0001 8.7
Bowel	incontinence IBS 1.9 .12 2.5
IBD 2.3 .004 2.9
Constipation IBS 6.9 <.0001 9.5
IBD 1.0 .21 1.3
IBD,	inflammatory	bowel	disease;	IBS,	irritable	bowel	syndrome.
Higher	 scores	 represent	 greater	 severity	 of	 symptoms.	All	 comparisons	 controlled	 for	 age,	 gender,	
race/ethnicity,	education,	and	marital	status.
TABLE  3 Symptom	domain	analysis	in	
irritable	bowel	syndrome	and	inflammatory	
bowel	disease	in	comparison	to	the	general	
population
FIGURE 2 Gastrointestinal	symptom	
severity	in	irritable	bowel	syndrome	(IBS)	
vs	the	general	population.	The	symptom	
domain	scores	for	the	general	population	
(GP,	gray	box)	and	the	IBS	patients	(black	
box)	are	shown.	The	IBS	patients	had	
significantly	higher	scores	(greater	severity)	
for	belly	pain,	gas/bloating,	diarrhea,	
constipation,	nausea,	and	vomiting	compared	
to	the	GP	(all	P<.05,	indicated	by	*)
S
ym
pt
om
 s
ev
er
ity
 s
co
re
10
40
50
60
70
Belly pain Gas and
bloating
Diarrhea Constipation Bowel 
incontinence
GER Disrupted 
swallowing
Nausea and 
vomiting
General population Irritable bowel syndrome
* * * *
* P <.05
*
6 of 9  |     LEE Et aL.
analysis	of	gender	differences	showed	that	overall,	women	reported	
more	 severe	 symptoms	of	 gas	 and	bloating	and	belly	pain,	 but	 less	
severe	 symptoms	 of	 bowel	 incontinence	 and	 disrupted	 swallowing	
than	men.
Patients	with	IBS	reported	more	severe	lower	GI	symptoms	includ-
ing	belly	pain,	constipation,	and	gas	and	bloating	than	their	IBD	and	
GP	counterparts.	These	results	are	consistent	with	a	prior	study	per-
formed	three	decades	ago,	showing	that	abdominal	distention,	strain-
ing	 at	 stool,	 and	 scybala	were	more	 likely	 in	 IBS	 than	 IBD.27 While 
bloating	is	a	symptom	that	can	often	be	seen	in	both	conditions,	it	is	a	
predominant	symptom	in	patients	with	functional	GI	disorders	partic-
ularly	IBS	and	chronic	constipation.28,29	In	addition,	IBS	has	a	greater	
female	predominance	than	IBD,	and	women,	more	so	than	men,	report	
symptoms	of	gas,	bloating,	and	constipation.30	Although	our	analysis	
is	limited	in	that	it	generalizes	symptoms	in	patients	with	IBS	and	IBD,	
without	accounting	for	temporal	variations	 in	disease	activity	or	the	
degree	 of	 IBD	 inflammation	 at	 the	 time	 of	 assessment,	 our	 results	
suggest	that	IBS	patients,	often	with	unremarkable	endoscopic	find-
ings,	have	more	severe	symptoms	than	patients	with	IBD,	a	condition	
whereby	disease	pathology	can	be	monitored	by	objective	inflamma-
tory	 and	 anatomic	 biomarkers.	The	 comparable	 severity	 of	 diarrhea	
and	bowel	incontinence	(as	opposed	to	constipation)	in	IBS	and	IBD	is	
not	unexpected	as	diarrhea	is	a	common	feature	of	both	GI	conditions.
The	 greater	 GI	 symptom	 severity	 seen	 in	 IBS	 patients	 is	 likely	
multifactorial.	 Patients’	 illness	 experience	 reflects	 upon	 how	 they	
perceive	their	sickness	in	the	context	of	psychosocial	and	demographic	
conditions.31	 IBS	 is	 a	 stress-	sensitive	 disorder	 in	which	 stress	 is	 as-
sociated	with	enhanced	colonic	motility	and	enhanced	visceral	percep-
tion.32,33	Hypervigilance,	an	 increased	attention	to	noxious	stimuli,	or	
an	 increased	 tendency	 to	 report	 sensations	as	bothersome	has	been	
demonstrated	in	IBS.34	In	fact,	patients	with	UC	in	remission	with	IBS	
symptoms	were	found	to	have	worse	GI	symptoms,	psychological	dis-
tress,	and	poorer	physical	and	mental	quality	of	life	than	patients	with	
UC	in	remission	without	IBS.35	Although	not	directly	examined	in	this	
study,	these	neurobiological	and	behavioral	changes	may	explain	why	
there	 is	significantly	greater	severity	of	GI	symptoms	in	 IBS	than	IBD	
and	 the	GP.	Prior	brain	 imaging	studies	have	suggested	 that	patients	
with	 IBS	 have	 increased	 activation	 of	 limbic	 and	 paralimbic	 circuits	
involved	with	emotional	 stress	 and	pain,	while	patients	with	UC	and	
healthy	controls	show	an	inhibition	of	these	central	pathways.36	This	is	
supported	clinically	by	the	fact	that	IBD	patients	showing	mild	inflam-
mation	of	their	disease	have	rectal	hyposensitivity	(i.e.,	lower	sensitivity)	
when	undergoing	rectal	distention	studies	compared	to	IBS	patients.37
We	also	found	significant	variation	in	upper	GI	symptom	severity	
among	IBS,	IBD,	and	GP.	Compared	to	the	GP,	IBD	patients	reported	
worse	 lower	 GI	 symptoms,	 but	 significantly	 less	 severe	 esophageal	
symptoms	than	the	GP.	Although	this	 is	a	novel	finding,	our	analysis	
is	limited	in	that	we	did	not	account	for	IBD	disease	phenotypes,	sub-
types,	or	disease	location.	It	should	also	be	noted	that	while	Crohn’s	
disease	can	affect	the	upper	GI	tract,	it	is	a	rare	phenomenon	and	only	
F IGURE  3 Gastrointestinal	symptom	severity	in	inflammatory	bowel	disease	(IBD)	vs	the	general	population.	The	symptom	domain	scores	
for	the	general	population	(GP,	gray	box)	and	the	IBD	patients	(white	box)	are	shown.	The	IBD	patients	had	significantly	higher	scores	(greater	
severity)	for	belly	pain,	gas/bloating,	diarrhea,	bowel	incontinence,	but	lower	severity	scores	for	gastro-	esophageal	reflux	(GER)	and	difficulty	
swallowing	compared	to	the	GP	(all	P<0.05,	indicated	by	*)
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F IGURE  4 Gastrointestinal	symptom	severity	in	irritable	bowel	syndrome	(IBS)	vs	inflammatory	bowel	disease	(IBD).	The	symptom	domain	
scores	for	the	IBS	patients	(black	box)	and	the	IBD	patients	(white	box)	are	shown.	The	IBS	patients	had	significantly	higher	scores	(greater	
severity)	for	belly	pain,	gas/bloating,	constipation,	gastro-	esophageal	reflux	(GER),	difficulty	swallowing,	and	nausea	and	vomiting	than	the	IBD	
patients	(all	P<0.05,	indicated	by	*)
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affects	0.5%–4%	of	patients	with	this	disease38	and	it	is	unlikely	that	
active	inflammation	has	significant	contribution	to	upper	GI	symptoms	
in	IBD.
Prior	studies	have	demonstrated	that	up	to	30%–40%	of	patients	
with	 IBS	will	 also	 report	 coexisting	 symptoms	 of	 GER,39,40	 but	 the	
prevalence	of	IBD	patients	reporting	GER	symptoms	has	not	been	well	
studied.	 In	 the	GP,	 the	prevalence	of	GER	ranges	from	10%	to	20%	
in	Western	 populations.41	A	 possible	 explanation	 for	 the	 decreased	
upper	GI	 symptom	 severity	 in	 IBD	 patients	 is	 that	 IBD	 is	 predomi-
nantly	a	disease	that	affects	 the	distal	bowel	 (ileum	and	colon)	with	
rare	involvement	of	the	upper	gastrointestinal	tract,	and	in	compari-
son,	these	patients	may	experience	relatively	less	severe	upper	tract	
symptoms	when	contrasted	to	their	severity	of	their	lower	GI	symp-
toms.	Evidence	supporting	this	is	based	on	prior	studies	demonstrating	
individuals	distracted	from	pain	will	often	report	diminished	pain	se-
verity.42,43	This	view	is	consistent	with	the	theory	of	attention-	related	
modulation	 of	 pain	 processing	 in	 which	 attention	 allocated	 toward	
symptoms	that	are	not	specific	to	a	particular	pain	will	diminish	the	
sensation	of	that	pain.44	An	alternative	explanation	for	these	findings	
is	that	all	of	the	surveyed	patients	with	IBD	and	IBS	were	under	the	
care	of	 gastroenterologists	who	may	have	been	adequately	 treating	
GER	symptoms	with	antireflux	measures.	This	may	also	explain	why	
patients	with	IBS	have	comparable,	rather	than	worse,	GER	symptoms	
than	the	GP.	Of	note,	we	previously	found	that	a	 larger	group	of	GI	
outpatients,	which	 included	our	patients	with	 IBS	 and	 IBD	but	 also	
others	with	diverse	GI	conditions	and	systemic	sclerosis,	had	worse	
regurgitation	but	similar	heartburn	symptoms	than	the	GP	using	the	
PROMIS®	GI	 Symptom	 items.17	The	prior	 inclusion	of	patients	with	
gastro-	esophageal	reflux	disease	(GERD)	and	systemic	sclerosis,	which	
commonly	 coexists	 with	 GERD,	 with	 GI	 symptoms	 in	 the	 previous	
study	likely	explains	these	differing	results.	Further	studies	should	be	
performed	 to	 investigate	 these	 results	 in	 the	 context	of	medication	
usage,	comorbidities,	IBS	and	IBD	disease	phenotypes	and	subtypes,	
and	IBD	disease	activity	and	location.
Women	had	more	severe	belly	pain,	gas,	and	bloating,	and	less	se-
vere	disrupted	swallowing	and	bowel	incontinence	than	men.	It	is	not	
surprising	that	women	reported	worse	symptoms	of	gas	and	bloating	
and	belly	pain	compared	 to	men,	as	 this	has	been	previously	shown	
in	large	cross-	sectional	population	studies.18,45	Furthermore,	these	are	
the	most	common	GI	symptoms	in	IBS,	and	this	group	had	a	greater	
proportion	of	women	than	the	other	two	groups	in	our	study,	partic-
ularly	 IBD.	 In	addition,	 the	finding	 that	men	 tended	 to	 report	worse	
symptom	severity	from	disrupted	swallowing	has	also	been	previously	
demonstrated	and	it	 is	thought	to	be	due	to	fact	that	women,	when	
compared	to	men,	have	more	preserved	pharyngeal	range	of	motion	
and	cough	reflex	as	they	age,	which	contributes	to	a	preserved	abil-
ity	to	swallow.46,47	 Interestingly,	 in	the	USA,	bowel	 incontinence	has	
been	reported	equally	among	genders,	but	may	be	more	prevalent	in	
younger	women.48	The	severity	of	symptoms	between	men	and	women	
has	been	shown	to	vary	significantly	depending	on	the	composition	of	
the	fecal	leakage.	Population	studies	indicate	that	while	women	report	
more	incontinence	from	liquid	and	solid	stools,	they	have	less	severe	
incontinence	 from	mucoid-	type	 stools.49,50	Our	 finding	 that	women	
report	 overall	 less	 severe	 symptoms	 from	 bowel	 incontinence	 than	
men	is	surprising,	however,	our	study	is	limited	in	that	we	did	not	dis-
tinguishing	between	type	of	bowel	 incontinence.	Further	studies	ex-
amining	gender	differences	in	bowel	incontinence	are	needed.
Our	 study	 has	 limitations.	We	 do	 not	 have	 information	 on	 the	
number	of	patients	with	IBD	who	also	would	concomitantly	meet	di-
agnostic	criteria	for	IBS.	A	recent	meta-	analysis	found	that	up	to	42%	
of	 IBD	patients	 can	have	 IBS-	like	 symptoms.51	However,	 this	meta-	
analysis	was	 limited	because	all	but	one	study	either	did	not	use	an	
objective	scoring	system	to	measure	disease	activity	in	IBD	or	did	not	
clearly	specify	if	the	objective	measures	that	were	used	to	determine	
disease	remission	were	obtained	at	the	same	time	IBS	symptoms	were	
assessed.52	In	addition,	we	found	significant	differences	in	our	IBD	and	
IBS	populations	with	regards	to	age,	gender,	race/ethnicity,	education	
level,	marital	status,	and	employment	status	which	may	reflect	inher-
ent	demographic	differences	 in	 these	diseases	or	may	be	 related	 to	
way	these	patients	were	recruited.	However,	our	analyses	controlled	
for	 these	demographic	 differences.	As	many	of	 these	patients	were	
recruited	 from	 specialty	 GI	 clinics,	we	 cannot	 exclude	 the	 fact	 our	
findings	may	 inherently	have	a	selection	bias.	For	example,	 IBD	and	
IBS	patients	who	visit	their	gastroenterologist	in	the	outpatient	setting	
may	be	more	likely	to	have	more	severe	disease	activity	and	symptoms	
than	those	who	do	not	regularly	follow-	up	with	a	physician,	although	
this	was	not	measured	in	our	study.	Similarly,	IBS	patients	who	were	
recruited	 from	a	mailing	 list	may	be	more	hypervigilant	and	 tend	 to	
report	more	 severe	 symptoms,	 however,	 only	 a	 very	 small	minority	
of	patients	were	recruited	in	this	manner.	In	the	case	of	IBD,	further	
studies	that	could	stratify	a	patient’s	IBD	symptoms	based	on	inflam-
matory	 biomarker	 levels,	 such	 as	C-	reactive	 protein	 or	 calprotectin,	
would	be	useful	to	help	confirm	our	findings.	Another	limitation	is	that	
we	are	not	able	 to	assess	GI	 symptom	severity	 in	 the	 subgroups	of	
IBS	(e.g.,	IBS-	D,	IBS-	C,	IBS-	M)	and	IBD	(i.e.,	Crohn’s	disease,	ulcerative	
colitis)	or	stratify	our	results	by	IBD	disease	activity,	phenotype	(e.g.,	
Montreal	or	Vienna	classification),	and	 location	due	to	the	relatively	
small	sample	sizes.
In	conclusion,	using	the	PROMIS®	GI	symptom	scales,	we	found	
significant	symptom	severity	differences	between	genders,	 IBS,	 IBD,	
and	 the	GP.	This	 study	 is	 unique	 in	 its	 ability	 to	 compare	 symptom	
perception	 in	 these	 disorders,	 and	 highlights	 the	 importance	of	 un-
derstanding	 the	 impact	of	brain–gut	 interactions	 in	GI	 symptom	as-
sessment.	Although	most	physicians	will	treat	objective	signs	of	IBD	
intestinal	 inflammation,	 IBS	 symptom	severity	may	not	primarily	 re-
flect	macroscopic	 or	microscopic	 inflammation,	 but	may	 rather	 rep-
resent	central	amplification	of	viscerosensory	input.	In	fact,	symptom	
severity	 assessment	 is	 arguably	more	 critical	 in	 the	management	of	
functional	GI	disorders	like	IBS	where	intestinal	inflammation	has	not	
been	consistently	demonstrated.	 It	 is	possible	that	the	PROMIS®	GI	
symptom	severity	scales	will	 correlate	better	with	objective	biologic	
markers	than	other	severity	 instruments	 in	 IBS	and	 IBD,	but	 further	
studies	 are	 needed.	 Future	 studies	 should	 also	 include	 prospective	
assessment	 of	 symptom	 severity	 in	well-	characterized	 IBS	 and	 IBD	
patients	to	confirm	our	findings,	and	also	determine	if	these	symptom	
scales	are	responsive	to	treatment	effects.
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